A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
NCT03742882
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
CC-90001
Sponsor
Celgene